Daniel C. Chung

TL;DR: Gene expression profiles reflect the current WHO classification and can distinguish benign from malignant P NETs and also PNETs from GI-NETs, and PDGFR and RET are candidates that may represent novel therapeutic targets.

TL;DR: The BMPCs are identified as alternative stromal targets of Hh-ligand in PDAC suggesting that the tumor vasculature is an attractive therapeutic target of HH blockade, consistent with the emerging concept that BM-derived cells make important contributions to epithelial tumorigenesis.

TL;DR: Abnormalities of the POS and rod dysfunction are the earliest central abnormalities observed in choroideremia, and foveal function is relatively preserved until the fifth decade of life.

TL;DR: Overexpression of cyclin D1 was identified in 43% of cases, and no correlation was observed with clinical phenotype, which suggests that this established oncogene may be implicated in the pathogenesis of human PETs.

TL;DR: The results of clinical trials have shown that the VEGF pathway inhibitor sunitinib and the mTOR inhibitor everolimus have efficacy in patients with advanced pancreatic NETs, suggesting that the molecular characterization of NETs may provide an avenue to predict both which patients may benefit most from the treatment and to overcome potential drug resistance.